logo

BME

BlackRock Health·NYSE
--
--(--)
--
--(--)
2.26 / 10
Underperform

The fundamental framework scores only 2.3/10, indicating subpar quality. Key concerns include a high Price-to-Sales ratio of 119.07 (PS factor, group 2), a negative Net Profit Margin of -41.11 (NPM, group 1), and an Asset-MV deficit of -0.0179 (group 1). Although Operating revenue shows a strong YoY growth of 405.36 (group 1), it is outweighed by other deteriorating metrics, leading to an overall 'Underperform' rating.

Fundamental(2.26)SentimentTechnical

Analysis Checks(5/10)

Revenue-MV
Value-0.22
Score1/3
Weight7.79%
1M Return1.08%
PS
Value119.07
Score2/3
Weight12.75%
1M Return1.86%
Profit-MV
Value-0.01
Score2/3
Weight10.15%
1M Return1.53%
Non-current assets / Total assets (%)
Value52.77
Score1/3
Weight13.91%
1M Return1.83%
GMAR
Value0.23
Score2/3
Weight5.67%
1M Return0.77%
NPM
Value-41.11
Score2/3
Weight11.83%
1M Return1.55%
Operating revenue (YoY growth rate %)
Value405.36
Score1/3
Weight11.79%
1M Return1.53%
Asset-MV
Value-0.02
Score1/3
Weight0.35%
1M Return0.05%
Inventory turnover days
Value389.25
Score3/3
Weight15.06%
1M Return1.93%
Current assets / Total assets (%)
Value47.71
Score0/3
Weight10.71%
1M Return1.49%
Is BME fundamentally strong?
  • BME scores 2.26/10 on fundamentals and holds a Premium valuation at present. Backed by its -0.68% ROE, -348.81% net margin, -20.88 P/E ratio, 1.07 P/B ratio, and -148.18% earnings growth, these metrics solidify its Underperform investment rating.